Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Deciphera Pharmaceuticals LLC"
Count: 14
Selected: 0
| NCT ID | Title |
|---|
| NCT04530981 | A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST | ||
| NCT05059262 | Study of Vimseltinib for Tenosynovial Giant Cell Tumor | ||
| NCT04892017 | A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors | ||
| NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies | ||
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | ||
| NCT05080621 | Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) | ||
| NCT03069469 | Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | ||
| NCT03601897 | A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | ||
| NCT03717415 | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | ||
| NCT03673501 | A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | ||
| NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | ||
| NCT02228811 | A Study of DCC-2701 in Participants With Advanced Solid Tumors | ||
| NCT00827138 | Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) | ||
| NCT02824575 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer |
